Papadopoulos Stelios
- SEC CIK
- 0001202098
In the past year, 1 open-market sale filing worth $4.36M and no purchases.
Current role at each company
- EXEL Exelixis, Inc.Directoras of May 29, 2026
- OVID Ovid Therapeutics Inc.Directoras of Apr 9, 2026
- RGLS Regulus Therapeutics Inc.Directoras of Jun 27, 2025
- BIIB Biogen Inc.Directoras of Jun 17, 2022
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- $4.36M
- 1 filing
- Net
- −$4.36M
- Bought minus sold
- Companies
- 1
- With open-market trades
Trades
Every Form 4 that lists Papadopoulos Stelios as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
EXEL Exelixis, Inc.
Director4 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 13, 2025 (view filing) | Nov 12 | 1 day | Papadopoulos SteliosDirector | SSale | −100.0K | $43.55 | −$4.36M | −7.8%1.19M after | |
| May 16, 2025 (view filing) | May 15 | 1 day | Papadopoulos SteliosDirector | SSale | −36.5K | $44.35 | −$1.62M | −2.8%1.28M after | 2 lots |
| May 22, 2024 (view filing) | May 20 | 2 days | Papadopoulos SteliosDirector | SSale | −11.4K | $21.00 | −$240.2K | −0.9%1.26M after | |
| Feb 24, 2022 (view filing) | Feb 22 | 2 days | Papadopoulos SteliosDirector | SSale | −84.5K | $19.56 | −$1.65M | −6.5%1.22M after |